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Abstract Background: The National Institute of Health’s Patient-Reported Outcomes Mea-
surement Information System (PROMIS) uses computerised-adaptive testing to reduce survey
burden and improve sensitivity. PROMIS is being used across medical and surgical disciplines
but has not been studied in orthopaedic oncology.
Questions/purposes: The aim of the study was to compare PROMIS measures with upper extrem-
ity (UE) and lower extremity (LE) Toronto Extremity Salvage Score (TESS) by assessing the
following: (1) responder burden, (2) correlation between scores and (3) floor/ceiling effects.
Patients and methods: This cross-sectional trial analysed all 97 adult patients treated surgically
for a bone or soft tissue tumour at a tertiary institution between November 2015 and March 2016.
TESS (UE or LE) and PROMIS (Physical Function, Pain Interference and Depression) surveys were
administered preoperatively. Pearson correlations between each PROMIS domain and TESS were
calculated, as were floor/ceiling effects of each outcome measure.
Results: (1) Completion of three PROMIS questionnaires required a mean total of 16.8 (þ/ 5.8
standard deviation) questions, comparedwith 31 and 32 questions for the LE and UE TESS question-
naires, respectively. (2) The PROMIS Physical Function scores demonstrated a strong positive
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correlation with the LE TESS (rZ 0.84; 95% confidence interval [CI], 0.72e0.91; p < 0.001) and
moderate positive correlationwith the UE TESS (rZ 0.64; 95% CI, 0.34e0.83; pZ 0.055). The PRO-
MIS Depression scores demonstrated aweak negative correlationwith both the LE TESS (rZ0.38;
95% CI, e0.61 to 0.10; p Z 0.010) and with UE TESS (r Z 0.38; 95% CI, e0.67 to 0.01;
pZ 0.055). The PROMIS Pain Interference scores demonstrated a strong negative correlation with
the LE TESS (rZ 0.71; 95% CI, e0.83 to 0.52; p < 0.001) and a moderate negative correlation
with the UE TESS (rZ0.62; 95% CI, e0.81 to0.30; pZ 0.001). (3) The UE TESS had a range of
scores from16 to 100with a 27% ceiling effect and no floor effect, and the LE TESS had a range from
10 to 98with nofloor or ceiling effect. Therewas nofloor or ceiling effect for any PROMISmeasures.
Conclusions: In an orthopaedic oncology population, the PROMIS Physical Function and Pain Inter-
ference scores correlate with the TESS and have the benefit of reduced survey burden and ceiling
effect. The PROMIS Depression scores may provide additional information regarding patient out-
comes not captured by the TESS.
Level of Evidence: Level III.
The translational potential of this article: Patient reported outcome measures asses patients’
symptoms, function and health-related quality of life and are designed to capturemore clinical in-
formation than can be gathered by objective medial testing alone. As reimbursements and the un-
derstanding of patient outcomes are becoming tied to performance on PROMIS measures, it is an
important step to establish how PROMIS measures correlate and compare to traditional legacy
measures.
ª 2019 TheAuthors. Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking Ortho-
paedic Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Historically, the speciality of musculoskeletal oncology
has relied on physician-dependent measurements
regarding patient function to compare outcomes of
treatment. In the 1980s, Enneking [14] described a clini-
cally based system to evaluate postoperative function of
sarcoma patients and to compare outcomes across
different treatment centres. Known as the Musculoskel-
etal Tumor Society (MSTS) rating scale, it is completed by
the clinician who rates the patient on seven parameters:
pain, range of motion, strength, joint stability, deformity,
emotional acceptances of the surgical procedure and
general functional ability. It has subsequently been
revised but is still completed by the physician. Thus, the
MSTS does not evaluate the patient’s perceived health or
functional capacity. Recently, the value of measuring a
patient’s perception of his or her function in response to
treatment has been widely recognized. In the last 2 de-
cades, there has been a transition from clinician-reported
outcome measures towards patient-reported outcome
(PRO) surveys as the former tends to underestimate
symptoms and physical function [6,4,28].
The Toronto Extremity Salvage Score (TESS) is a physical
disability measure developed specifically for patients un-
dergoing surgery for extremity tumours and has been shown
to have superior measurement properties compared with
other commonly used scales [12,10]. It was developed in an
effort to improve on the MSTS scoring system and address
patient perspectives; thus, the item content was based on
patient suggestions and feedback. It consists of 31 ques-
tions that gauge the patient’s physical function by querying
the difficulty of performing activities of daily living and
recreation. The TESS questionnaire was developed by the
members of a multidisciplinary sarcoma treatment team
including surgeons, physical and occupational therapists
and nurses of the University of Toronto. This group worked
together to identify specific types of functional difficulty
experienced by sarcoma patients within the domains of
daily living, work or school, leisure, mobility and sexual
activity. A preliminary questionnaire was then mailed to
the sarcoma patients, who rated the level of difficulty
experienced with each particular activity, as well as the
importance of the activity. Difficulty and importance fre-
quencies were calculated, and items rated “total unim-
portant” or “not applicable” by 30% of the respondents
were eliminated. Validation testing also assessed internal
consistency and testeretest reliability of the TESS [12]. The
TESS questionnaire is administered on paper and scored
using a Microsoft Excel algorithm.
Although the TESS is currently the most commonly re-
ported patient-reported measure in musculoskeletal
oncology, several systems are currently used, which increases
the challenge of comparing and combining data [11,10,27]. In
addition, musculoskeletal oncology presents unique chal-
lenges for developing a patient-reported survey, as the het-
erogeneity of the population is quite broad across age,
diagnosis, extent of limb involvement, type of resection and
reconstruction or prosthetic options. A standard patient-
reported survey would need to be exhaustive to capture the
diverse spectrum of outcomes in musculoskeletal oncology,
leading to long completion times, survey fatigue and rela-
tively high floor and ceiling effects. The Patient-Reported
Outcomes Measurement Information System (PROMIS), a
computerised-adaptive testing (CAT) measure recently
developed by the National Institutes of Health, represents a
potentially universal measurement tool with the advantage of
reduced burden on patients [32]. Computer adaptive tests use
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item response theory, a technique that selects each survey
question based on the respondent’s previous answer. It
eliminates the need to respond to overlapping and repetitive
items yet still yields precise measurements regarding patient
function [3]. CAT is completed when the consistency of the
answers is sufficient for scoring. PROMIS CAT has been studied
in several orthopaedic populations [20], specifically including
hand and shoulder [1,2,8,13,24,25,32], foot and ankle [18],
sports [16,28], adult reconstruction [20], spine [30] and
trauma [19,18,21,33,29,1,2,8,13,16,20,25,31], as well as
various oncologic subspecialities [15,34,5,9]. There is
currently a widespread initiative for adoption and inclusion of
PROMIS domains in all Federal Drug Administratione
funded and industry-funded clinical oncology outcome
research. In addition, the Federal Drug Administration is
working to approve the PROMIS Physical Function score for use
as a clinical outcome assessment in adults with advanced solid
tumours. If successful, this will lead to a standard PRO mea-
sure of physical function for use in future industry-sponsored
clinical trials, intended for registration of newoncology drugs.
Despite the growing importance of PROMIS in oncology
and orthopaedics, its role in orthopaedic oncology has not
yet been established. The purpose of this study was to
compare the performance of PROMIS relative to the upper
extremity (UE) and lower extremity (LE) TESS by quanti-
fying responder burden, determining the correlation be-
tween scores and assessing floor and ceiling effects for each
outcome measure.
Methods
Approval was obtained from the institutional review board
at Washington University in Saint Louis School of Medicine,
and informed consent was obtained from all patients. This
cross-sectional study included all new patients who un-
derwent surgical treatment for primary and metastatic
bone or soft tissue tumour and who were consecutively
evaluated in the outpatient setting by the orthopaedic
oncology service at a single university-based tertiary care
institution between November 2015 and March 2016. The
patients whose preoperative evaluation took place only in
the emergency department or inpatient setting were
excluded. Pregnant women and non-English speaking in-
dividuals were excluded.
Preoperative TESS and PROMIS (Depression, Pain Inter-
ference and Physical Function) scores were self-
administered to all patients within 60 days of surgery.
The TESS survey was completed on paper and manually
entered into a secure database, whereas the PROMIS survey
was administered using a tablet computer (mini iPad;
Apple, Palo Alto, CA), collected over a secure wireless
network, immediately scored and deposited into the elec-
tronic medical record. The TESS questionnaire was admin-
istered on paper and scored using a Microsoft Excel
algorithm. The PROMIS measures are available in a
computerized adaptive testing (CAT) format and are
normalized to a standard population distribution with a
mean of 50 and a standard deviation of 10 which simplifies
comparisons between the treatment groups. PROMIS as-
sessments are scored so that a higher score represents more
of each item being measured. For example, a higher
Depression score represents more depressive symptoms,
whereas a higher Physical Function score represents better
function. Of the 97 patients (70 LE and 27 UE patients), two
LE patients were excluded for an incomplete TESS survey.
Our sample size calculation indicated that 47 patients
would provide 80% power to detect a minimum of a mod-
erate correlation (r Z 0.40) with an alpha of 0.05 [17].
Correlation between each PROMIS measure and the LE and
UE TESS was assessed using the Pearson coefficient using
the statistical program R (R Foundation for Statistical
Computing, Vienna, Austria), and the floor and ceiling ef-
fect of each PROMIS measure was calculated and compared
with that of the LE and UE TESS. Correlation coefficients
were calculated with 95% confidence intervals (CIs) and
interpreted according to Evans [24] (0.00e0.19, very weak;
0.20e0.39, weak; 0.40e0.59, moderate; 0.60e0.79, strong;
and 0.80e1.00, very strong).
Results
Our population of 97 patients had a mean age of 53 years
and a mean tumour size of 6.7 cm. There were more soft
tissue tumours than bone tumours, more LE tumours than
UE tumours, and more malignant tumours than benign tu-
mours (Table 1). Completion of PROMIS questionnaires
required a mean of 4.4 questions (þ/ 1.3 standard devi-
ation [SD]) for Physical Function, 6.8 (þ/3.5 SD) for Pain
Table 1 Demographics and tumour characteristics in the
patient population.
Patient/tumour characteristics Mean (range)
Patient age (years) 53 (12e91)
Tumour size (cm) 6.7 (0.5e23)
Number (%)
Upper extremity tumours 27 (28%)
Lower extremity tumours 70 (72%)
Soft tissue tumours 55 (57%)
Bone tumours 42 (43%)
Benign tumours 37 (38%)
Malignant tumours 60 (62%)
Table 2 Number of questions required for evaluation
using PROMIS and TESS surveys.





Physical function CAT 4.4 1.3 4e12
Pain interference CAT 6.8 3.5 4e12
Depression CAT 5.6 3.0 4e12
Total PROMIS (3 domains) 16.8 5.8 12
e36
TESS LE 31 n/a n/a
TESS UE 32 n/a n/a
CAT, computerised-adaptive testing; LE, lower extremity;
PROMIS, Patient-Reported Outcomes Measurement Information
System; SD, standard deviation; TESS, Toronto Extremity
Salvage Score; UE, upper extremity.
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Interference and 5.6 (þ/3.0 SD) for Depression. The
combined PROMIS measures, including all three domains,
required a mean of 16.8 (þ/ 5.8 SD) questions to com-
plete, compared with 31 and 32 questions for the LE and UE
TESS questionnaires, respectively (Table 2).
The PROMIS Physical Function score demonstrated a very
strong positive correlation with the LE TESS (r Z 0.84; 95%
CI, 0.72e0.91; p < 0.001) and a strong positive correlation
with the UE TESS (r Z 0.64; 95% CI, 0.34e0.83; p Z 0.055)
(Fig. 1A). The PROMIS Depression scores demonstrated a
weak negative correlation with both the LE TESS
(r Z 0.38; 95% CI, e0.61 to 0.10; p Z 0.010) and UE
TESS (r Z 0.38; 95% CI, e0.67 to 0.01; p Z 0.055)
(Fig. 1B). The PROMIS Pain Interference scores demon-
strated a strong negative correlation with the LE TESS
(r Z 0.71; 95% CI, e0.83 to 0.52; p < 0.001) and a
moderate negative correlation with the UE TESS
(r Z 0.62; 95% CI, e0.81 to e0.30; p Z 0.001) (Fig. 1C).
The UE TESS had a range of scores from 16 to 100 with a
27% ceiling effect and no floor effect, and the LE TESS had a
range from 10 to 98 with no floor or ceiling effect. PROMIS
Depression, Pain Interference and Physical Function scores
ranged from 34 to 78, 39 to 78 and 20 to 73 for LE patients
and from 34 to 76, 37 to 80 and 24 to 70 for UE patients.
There was no floor or ceiling effect for any PROMIS measures.
Discussion
This study included a heterogeneous patient sample, with
various ages, diagnoses and treatments, demonstrating the
ability of the PROMIS to accurately score function in pa-
tients with substantial disability and those with very high
function. On an average, completion of the three PROMIS
domains combined required half as many questions as the
UE or LE TESS survey. The PROMIS Physical Function scores
demonstrated a strong positive correlation with the LE TESS
and a moderate positive correlation with the UE TESS; the
Pain Interference scores demonstrated a strong negative
correlation with the LE TESS and a moderate correlation
with the UE TESS; the Depression scores demonstrated a
moderate negative correlation with both the LE TESS and
UE TESS. The UE TESS had a 27% ceiling effect, whereas
there was no floor or ceiling effect in the LE TESS or any of
the PROMIS measures.
Our study has several limitations. Although our LE sample
size was adequate to detect a medium effect size, there
were only enough UE patients to detect a large effect size.
Thus, a larger cohort may have demonstrated stronger re-
lationships between the TESS and PROMIS, particularly in UE
measures and Depression scores. In addition, a diverse group
of patients was included, and our cohort was not large
enough for subgroup analysis other than UE versus LE tu-
mours. Therefore, although our results are generalizable,
additional information may be gained from analysis by
diagnosis and other variables in a larger study. Finally, our
study was based only on preoperative scores, and therefore,
the results may not apply to a postoperative assessment. It
is possible that the TESS and PROMIS measures may differ in
how they measure tumour-related symptoms versus surgical
outcomes or additional floor/ceiling effects may be present
in the postoperative population.
Responder burden
The PROMIS physical function (PF) CAT questionnaire
required a mean of only 4.4  1.3 questions for completion,
compared with the standard 30-question item TESS ques-
tionnaire. In general, longer surveys provide more infor-
mation regarding outcomes but at the expense of attrition
and survey fatigue. CAT can optimize reliability while
minimizing the number of items needed to capture a pre-
cise outcome score. In traditional outcome measures,
scores at the limits of surveys tend to have more error than
that in the middle range, whereas item response in CAT is
able to achieve measurement precision over a range of
ability scores [3], as demonstrated by our data. PROMIS PF
correlates most strongly with TESS because both are mea-
sures of physical function. The algorithm for the PROMIS
Physical Function domain selects from a total of 124 ques-
tions garnered from a variety of legacy outcome measures,
representing a broader set of questions than represented in
non-CAT questionnaires, such as the - TESS. This explains
the high accuracy and precision of the algorithm of the
PROMIS Physical Function, despite the smaller number of
questions answered.
Obtaining PROs in an efficient and timely manner is key
to reducing patient burden and attrition, as well as in
providing the clinician with key information to help guide
treatment decisions. Our study did not evaluate time of
completion of surveys; however, previous studies have well
documented that PROMIS CAT is faster to complete than the
standard accepted PRO measures. In a previous study,
comparing TESS versus PROMIS physical function in patients
with LE bone metastases, 73% of the participants
completed the PROMIS Physical Function survey within
1 min compared with an average completion time of more
than 4 min for the TESS survey [23]. In a study comparing
PROMIS scores with the disabilities of the arm, shoulder and
hand (DASH) scores in patients with UE conditions, the
participants completed the PROMIS PF survey in an average
of 57 s compared with 262 s for the DASH survey [33].
Similarly, in a study of the validation of PROMIS PF in foot
Figure 1 Pearson correlation plots demonstrating the relationship between TESS and PROMIS scores. (A) PROMIS Physical
Function scores had a strong positive correlation with the LE TESS (r Z 0.84, p < 0.001) and a moderate positive correlation with
the UE TESS (r Z 0.64, p Z 0.055). (B) PROMIS Pain Interference scores had a strong negative correlation with the LE TESS
(r Z 0.71, p < 0.001) and a moderate negative correlation with the UE TESS (r Z 0.62, p Z 0.001). (C) PROMIS Depression
scores had a weak negative correlation with the LE TESS (r Z 0.38, p Z 0.010) and a weak correlation with the UE TESS
(r Z 0.38, p Z 0.055).
LE, lower extremity; PROMIS, Patient-Reported Outcomes Measurement Information System; TESS, Toronto Extremity Salvage
Score; UE, upper extremity.
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and ankle patients, the participants completed the survey
with an average time of only 47 s [18].
Correlation
In our study population, correlation between the PROMIS
CAT survey and TESS in an orthopaedic oncology clinic
varied based on the anatomic location and outcome mea-
sure. In our LE cohort, the TESS had a strong positive cor-
relation with the PROMIS Physical Function scores, a strong
negative correlation with the PROMIS Pain Interference
scores and a weak negative correlation with the PROMIS
Depression scores in patients with LE tumours. In UE pa-
tients, the TESS had a moderate positive correlation with
the PROMIS Physical Function scores, a moderate negative
correlation with the PROMIS Pain Interference scores and a
weak negative correlation with the PROMIS Depression
scores. Of note, higher PROMIS Depression and Pain Inter-
ference scores indicate greater depression and pain,
explaining the inverse relationship to the TESS, in which
higher scores indicate superior outcomes. The greater
strength of the LE correlations is likely attributable, at
least in part, to the larger number of patients in that group
and the ceiling effect observed with the UE TESS in the
following section. It is also possible that functional
compromise has a more profound effect on disability when
it occurs in the LE compared with the UE. The PROMIS
Physical Function survey has demonstrated good correlation
with the DASH survey, a common PRO for UE function
[33,22]. This suggests that the weaker correlation between
the UE TESS and PROMIS PF scores may be related to limi-
tations of the UE TESS than the PROMIS.
Finally, the weak correlation with the PROMIS Depression
scores in both UE and LE tumours confirms that the TESS was
designed to measure function and pain but not depression.
However, the Depression scores still demonstrated some
negative association with the TESS scores suggesting an
interrelationship between depressive symptoms and
perceived function. A PROMIS Depression score 59.9 has
been shown to correspond to a score of 10 in the Patient
Health Questionnaire-9, which indicates moderate depres-
sion [34,35]. Eighteen percent of our patient population
reported scores above this threshold at some point during
the time frame of the study. Additional research will be
necessary to better understand the implications of depres-
sive symptoms in the practice of orthopaedic oncology.
Floor/ceiling effects
A substantial ceiling effect was observed for the UE TESS
score, which contributed to the weaker correlation be-
tween TESS and PROMIS scores in patients with UE tumours.
There was no appreciable ceiling or floor effect for any of
the other measures. The elimination of this UE TESS ceiling
effect would be a substantial improvement in the assess-
ment of patients with UE tumours. Importantly, the PROMIS
Physical Function CAT does not appear to suffer the same
ceiling effect. Of note, the PROMIS Physical Function CAT is
designed to assess overall function, rather than extremity-
specific function. Although the PROMIS Physical Function
CAT has been criticized for disproportionally providing
questions related to LE function, previous studies have
shown a strong correlation with traditional UE
patientereported outcomes [33,26,30]. The more recently
developed PROMIS UE CAT, which was designed to specif-
ically assess UE function, may have increased sensitivity to
capture UE impairment. However, similar to the UE TESS,
the PROMIS UE CAT has demonstrated a ceiling effect [7,8].
Conclusions
The patients in our study cohort completed all three PROMIS
domains combined in half as many questions as the TESS
survey. The PROMIS Physical Function and Pain Interference
scores correlated strongly with the TESS for LE; the corre-
lation was weaker for UE tumours, likely related to the
substantial ceiling effect observed for the UE TESS. The
PROMIS Depression domain is not measured by the TESS.
Potential advantages of the PROMIS over TESS include
assessing functional outcomes with greater efficiency
(fewer questions) and accuracy (reduced ceiling effect), as
well as capturing additional quality of life and mental health
outcomes such as Pain Interference and Depression. Larger,
long-term studies are needed to further validate PROMIS
measures and their applications in orthopaedic oncology.
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